A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Trial Profile

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs KD 018 (Primary) ; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jul 2017 Status changed from recruiting to suspended.
    • 13 Jun 2014 Planned number of patients changed from 54 to 165, Phase changed from IB/II to II and study included an additional placebo arm. Also, primary endpoints and study inclusion/exclusion criteria have been updated accordingly.
    • 13 Jun 2014 Planned number of patients changed from 54 to 165 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top